Cargando…

Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making

PURPOSE: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines...

Descripción completa

Detalles Bibliográficos
Autores principales: Perlow, Haley K., Cassidy, Vincent, Farnia, Benjamin, Kwon, Deukwoo, Awerbuch, Adam W., Ciraula, Stephanie, Alford, Scott, Griggs, Jacob, Quintana, Joseph A., Yechieli, Raphael, Samuels, Stuart E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349604/
https://www.ncbi.nlm.nih.gov/pubmed/30706020
http://dx.doi.org/10.1016/j.adro.2018.09.002
_version_ 1783390287563849728
author Perlow, Haley K.
Cassidy, Vincent
Farnia, Benjamin
Kwon, Deukwoo
Awerbuch, Adam W.
Ciraula, Stephanie
Alford, Scott
Griggs, Jacob
Quintana, Joseph A.
Yechieli, Raphael
Samuels, Stuart E.
author_facet Perlow, Haley K.
Cassidy, Vincent
Farnia, Benjamin
Kwon, Deukwoo
Awerbuch, Adam W.
Ciraula, Stephanie
Alford, Scott
Griggs, Jacob
Quintana, Joseph A.
Yechieli, Raphael
Samuels, Stuart E.
author_sort Perlow, Haley K.
collection PubMed
description PURPOSE: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. METHODS AND MATERIALS: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). RESULTS: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P = .029) and both fair (P = .051) and poor (P = .065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P = .871). CONCLUSIONS: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.
format Online
Article
Text
id pubmed-6349604
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63496042019-01-31 Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making Perlow, Haley K. Cassidy, Vincent Farnia, Benjamin Kwon, Deukwoo Awerbuch, Adam W. Ciraula, Stephanie Alford, Scott Griggs, Jacob Quintana, Joseph A. Yechieli, Raphael Samuels, Stuart E. Adv Radiat Oncol Palliative Care PURPOSE: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. METHODS AND MATERIALS: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). RESULTS: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P = .029) and both fair (P = .051) and poor (P = .065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P = .871). CONCLUSIONS: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling. Elsevier 2018-09-14 /pmc/articles/PMC6349604/ /pubmed/30706020 http://dx.doi.org/10.1016/j.adro.2018.09.002 Text en © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Palliative Care
Perlow, Haley K.
Cassidy, Vincent
Farnia, Benjamin
Kwon, Deukwoo
Awerbuch, Adam W.
Ciraula, Stephanie
Alford, Scott
Griggs, Jacob
Quintana, Joseph A.
Yechieli, Raphael
Samuels, Stuart E.
Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title_full Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title_fullStr Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title_full_unstemmed Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title_short Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making
title_sort impact of performance status and comorbidity on palliative radiation treatment tolerance and end-of-life decision-making
topic Palliative Care
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349604/
https://www.ncbi.nlm.nih.gov/pubmed/30706020
http://dx.doi.org/10.1016/j.adro.2018.09.002
work_keys_str_mv AT perlowhaleyk impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT cassidyvincent impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT farniabenjamin impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT kwondeukwoo impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT awerbuchadamw impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT ciraulastephanie impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT alfordscott impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT griggsjacob impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT quintanajosepha impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT yechieliraphael impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking
AT samuelsstuarte impactofperformancestatusandcomorbidityonpalliativeradiationtreatmenttoleranceandendoflifedecisionmaking